Valion Bio, Inc. — Form 8-K
Filed August 27, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Valion Bio (NASDAQ: VBIO), a $4M market-cap biotech company, implemented a 1-for-25 reverse stock split effective August 31, 2026, to restore compliance with Nasdaq's minimum $1.00 bid price requirement. The company had received a non-compliance notice on March 19, 2026, and had until September 15, 2026, to remedy the deficiency. The reverse split reduces outstanding shares proportionally; fractional shares are rounded up to whole shares with no cash settlements, and all warrant, option, and equity award exercise prices and share counts are adjusted proportionately.
Why this rating
Reverse split is material for a $4M-cap company facing delisting risk—business continuity depends on exchange listing. However, split itself does not change fundamentals; success depends on whether stock price rebounds above $1 post-split.
Tradability signal
NO TRADE
No trade: price $0.14 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.13 ▼ 4.60% | at our read · backfill $0.14 | +10 min · backfill $0.15 ▲ 5.04% | +30 min · backfill $0.15 ▲ 9.86% | +1 hr · backfill $0.15 ▲ 5.76% | +4 hrs · backfill $0.13 ▼ 9.35% |
The stock had already moved +4.83% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.